{"id":153176,"title":"Use of conjugate pneumococcal vaccine – 15 valent (PNEU-C-15) and 20 valent (PNEU-C-20) in adults: NACI recommendations: Economic evidence supplementary appendixrecommendations. - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2025-04-18","captureTimestamp":"2025-04-18T12:20:23.035000+00:00","jobId":1,"originalUrl":"https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/public-health-level-recommendations-use-pneumococcal-vaccines-adults-including-use-15-valent-20-valent-conjugate-vaccines/economic-evidence-supplementary-appendix.html","snippet":"Use of conjugate pneumococcal vaccine – 15 valent (PNEU-C-15) and 20 valent (PNEU-C-20) in adults: NACI recommendations: Economic evidence supplementary appendixrecommendations. - Canada.ca Skip to main content Skip to \"About government\" Language selection Français fr /…","rawSnapshotUrl":"/api/snapshots/raw/153176","browseUrl":"https://replay.healtharchive.ca/job-1/20250418122023/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/public-health-level-recommendations-use-pneumococcal-vaccines-adults-including-use-15-valent-20-valent-conjugate-vaccines/economic-evidence-supplementary-appendix.html#ha_snapshot=153176","mimeType":"text/html","statusCode":200}